Aluba, Emma .
HRN: 26-79-88 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/22/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
03/22/2025
03/28/2025
IV
2.25g
Q8h
Acute Pyelonephritis
Waiting Final Action
Indication: Empiric Type of Infection: Urinary Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes